Ryanodex
Total Payments
$625,640
Transactions
627
Doctors
573
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1,472 | 18 | 18 |
| 2023 | $4,849 | 204 | 204 |
| 2022 | $2,262 | 109 | 106 |
| 2021 | $6,516 | 173 | 173 |
| 2020 | $408,732 | 60 | 51 |
| 2019 | $201,810 | 63 | 52 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $514,671 | 13 | 82.3% |
| Charitable Contribution | $68,561 | 8 | 11.0% |
| Food and Beverage | $20,119 | 601 | 3.2% |
| Consulting Fee | $17,500 | 2 | 2.8% |
| Travel and Lodging | $4,789 | 3 | 0.8% |
Payments by Type
Research
$514,671
13 transactions
General
$110,969
614 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TO ASSESS THE POTENTIAL NEUROPROTECTIVE EFFECTS AND SAFETY OF INTRANASAL ADMINISTRATION OF DANTROLENE IN A 5XFAD ALZHEIMER S DISEASE MOUSE MODEL. | Eagle Pharmaceuticals, Inc. | $277,170 | 0 |
| A PILOT TRIAL TO DEMONSTRATE THE FEASIBILITY OF USING DANTROLENE TO STUDY RYR2 INHIBITION TO PREVENT VENTRIBULAR ARRHYTHMIAS - AHA STRATEGICALLY FOCUSED RESEARCH NETWORK | Eagle Pharmaceuticals, Inc. | $59,655 | 0 |
| STUDY IS TO EVALUATE RYANODEX AS A TREATMENT FOR TRAUMATIC BRAIN INJURY TBI IN A RODENT TBI MODEL | EAGLE PHARMACEUTICALS, INC. | $56,400 | 0 |
| EVALUATION OF THE EFFICACY OF RYANODEX AS A TREATMENT FOR TRAUMATIC BRAIN INJURY IN A RODENT MODEL | EAGLE PHARMACEUTICALS, INC. | $44,454 | 0 |
| ACADEMIC STUDY | Eagle Pharmaceuticals, Inc. | $32,539 | 0 |
Top Doctors Receiving Payments for Ryanodex — Page 22
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Anesthesiology | Evansville, IN | $13.03 | 1 |
| , M.D | Addiction Medicine | Danville, KY | $13.03 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Danville, KY | $13.03 | 1 |
| , APRN | Acute Care | Danville, KY | $13.03 | 1 |
| Tami Lamy | — | Covington, LA | $12.95 | 1 |
| , PAAA | Anesthesiologist Assistant | Lawrenceville, GA | $12.82 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Chattanooga, TN | $12.82 | 1 |
| , MD | Anesthesiology | Lawrenceville, GA | $12.82 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Lawrenceville, GA | $12.82 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Atlanta, GA | $12.82 | 1 |
| , PA | Anesthesiologist Assistant | Atlanta, GA | $12.82 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Conyers, GA | $12.82 | 1 |
| , AA | Anesthesiologist Assistant | West Palm Beach, FL | $12.81 | 1 |
| Gregg Snider | — | Lawrenceville, GA | $12.81 | 1 |
| Nebiyu Muleta | Nurse Anesthetist, Certified Registered | Atlanta, GA | $12.81 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Lawrenceville, GA | $12.81 | 1 |
| , PAAA | Anesthesiologist Assistant | Lawrenceville, GA | $12.81 | 1 |
| , MD | Anesthesiology | Jasper, GA | $12.81 | 1 |
| , PAAA | Anesthesiologist Assistant | Lawrenceville, GA | $12.81 | 1 |
| , MD | Anesthesiology | Lawrenceville, GA | $12.81 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | New Orleans, LA | $12.80 | 1 |
| , PAAA | Physician Assistant | Atlanta, GA | $12.80 | 1 |
| , PAAA | Anesthesiologist Assistant | Lawrenceville, GA | $12.80 | 1 |
| , APRN, CRNA | Nurse Anesthetist, Certified Registered | New Orleans, LA | $12.80 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Atlanta, GA | $12.80 | 1 |
Ad
Manufacturing Companies
- Eagle Pharmaceuticals, Inc. $487,758
- EAGLE PHARMACEUTICALS, INC. $137,882
Product Information
- Type Drug
- Total Payments $625,640
- Total Doctors 573
- Transactions 627
About Ryanodex
Ryanodex is a drug associated with $625,640 in payments to 573 healthcare providers, recorded across 627 transactions in the CMS Open Payments database. The primary manufacturer is Eagle Pharmaceuticals, Inc..
Payment data is available from 2019 to 2024. In 2024, $1,472 was paid across 18 transactions to 18 doctors.
The most common payment nature for Ryanodex is "Unspecified" ($514,671, 82.3% of total).
Ryanodex is associated with 5 research studies, including "TO ASSESS THE POTENTIAL NEUROPROTECTIVE EFFECTS AND SAFETY OF INTRANASAL ADMINISTRATION OF DANTROLENE IN A 5XFAD ALZHEIMER S DISEASE MOUSE MODEL." ($277,170).